March 21, 2025Johnson & Johnson Neurovascular leader heads for the exit ~1 min.Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....
March 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals ~2 min.Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....
March 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy ~1 min.Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....
March 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader ~1 min.Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....
March 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments ~1 min.Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
January 15, 2025JJ to buy psychiatric drug developer Intra-Cellular for 14.6B ~2 min.In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion....
November 14, 2024AbbVie Faces Setback as Schizophrenia Drug Trials Fall Short ~2 min.Pharmaceutical giant AbbVie Inc. (ABBV) experienced a significant drop in stock prices today, following disappointing results from their latest schizophrenia drug trials....
November 12, 2024AbbVie Stock Faces Setback as Schizophrenia Drug Trials Disappoint ~1 min.Shares of AbbVie Inc. (ABBV) took a hit today after the results of the company's schizophrenia drug trials fell short of expectations....
November 16, 2024The Motley Fool - AbbVie Stock: Keep Calm And Buy The Dip ~1 min.AbbVie Inc. (ABBV) experienced a decline in stock value today after disappointing results from its schizophrenia drug trials. However, some investors may see this as a buying opportunity....
November 17, 2024Why AbbVie's ABBV Drug Setback Creates A Prime Buy-The-Dip Moment ~1 min.AbbVie Inc. (ABBV) shares took a hit today after disappointing results from its schizophrenia drug trials. However, this setback presents a unique buying opportunity for investors....
